Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review

IF 4 3区医学 Q1 PHARMACOLOGY & PHARMACY Current Opinion in Pharmacology Pub Date : 2023-12-30 DOI:10.1016/j.coph.2023.102424

Betsy Benitez , Abdelrahman M. Anter , Jennifer Arcuri , Sanjoy K. Bhattacharya

{"title":"Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review","authors":"Betsy Benitez , Abdelrahman M. Anter , Jennifer Arcuri , Sanjoy K. Bhattacharya","doi":"10.1016/j.coph.2023.102424","DOIUrl":null,"url":null,"abstract":"<div>Recent advancements in prostaglandin analogs (PGAs) have reinforced their role in managing intraocular pressure (IOP). Latanoprost excels in 24-h IOP control, while various PGAs offer similar effectiveness and side effects, generic PGAs perform as well as branded ones, and a notable IOP rise observed upon PGA discontinuation. Formulations with or without preservatives show comparable IOP reduction and adherence, often surpassing benzalkonium chloride (BAK)-preserved options. Emergent PGAs, such as latanoprostene bunod, fixed-dose netarsudil combined with latanoprost, and omidenepag Isopropyl, offer enhanced or non-inferior IOP reduction. The bimatoprost implant introduces a novel administration method with effective IOP reduction. These developments underscore ongoing progress in PGA-focused ophthalmological research. This article offers a comprehensive review of available prostanoid analogs and explores new developments.</div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1471489223000796","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Recent advancements in prostaglandin analogs (PGAs) have reinforced their role in managing intraocular pressure (IOP). Latanoprost excels in 24-h IOP control, while various PGAs offer similar effectiveness and side effects, generic PGAs perform as well as branded ones, and a notable IOP rise observed upon PGA discontinuation. Formulations with or without preservatives show comparable IOP reduction and adherence, often surpassing benzalkonium chloride (BAK)-preserved options. Emergent PGAs, such as latanoprostene bunod, fixed-dose netarsudil combined with latanoprost, and omidenepag Isopropyl, offer enhanced or non-inferior IOP reduction. The bimatoprost implant introduces a novel administration method with effective IOP reduction. These developments underscore ongoing progress in PGA-focused ophthalmological research. This article offers a comprehensive review of available prostanoid analogs and explores new developments.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

目前可用于治疗青光眼和眼压过高的前列腺素：综述

前列腺素类似物（PGA）的最新进展加强了其在控制眼压（IOP）方面的作用。拉坦前列素在 24 小时眼压控制方面表现出色，而各种前列腺素类似物具有相似的疗效和副作用，非专利前列腺素类似物的表现不亚于品牌前列腺素类似物，但停用前列腺素类似物后眼压会明显升高。含防腐剂或不含防腐剂的制剂在降低眼压和依从性方面的表现不相上下，通常超过含苯扎氯铵（BAK）防腐剂的制剂。新出现的 PGA，如拉坦前列腺素布诺、固定剂量的奈达昔洛联合拉坦前列腺素和奥美替尼帕格异丙戊等，可提高或降低眼压。比马前列素植入剂引入了一种新的给药方法，可有效降低眼压。这些发展凸显了以 PGA 为重点的眼科研究的不断进步。本文全面回顾了现有的类前列腺素类似物，并探讨了新的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Opinion in Pharmacology 医学-药学

CiteScore

8.80

自引率

2.50%

发文量

131

审稿时长

4-8 weeks

期刊介绍： Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.

期刊最新文献

Editorial Board Role of specific CDKs in regulating DNA damage repair responses and replication stress Therapeutic innovations for geographic atrophy: A promising horizon Targeting the soluble epoxide hydrolase pathway as a novel therapeutic approach for the treatment of pain Native botulinum toxin type A vs. redesigned botulinum toxins in pain: What did we learn so far?